MTHFD2 and neoplasm: Upregulated MTHFD2 was reported to support multiple tumor phenotypes, including proliferation [11–16, 20, 24–30, 33–35, 41–43, 45], migration [10, 13, 22, 25, 27, 28, 33, 34], invasion [10, 13, 16, 22, 25], metastasis [26, 34, 43], drug resistance [17, 32, 35, 36, 38, 45], immune evasion [46], metabolic reprogramming [8, 12, 24], self-renewal [30, 32], and poor prognosis of patients [9, 17, 18, 21–23, 25, 26, 31, 33–35, 37, 39, 40, 42].